Daiichi Sankyo studies esaxerenone in Phase III trial for diabetic nephropathy

Japanese pharmaceutical firm Daiichi Sankyo has started a Phase III clinical trial (ESAX-DN) of its product candidate esaxerenone to treat diabetic nephropathy in the country.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news